Identification of potential genomic biomarkers for early detection of chemically induced cardiotoxicity in rats

Toxicology

Volumn 271, Issue 1-2, 2010, Pages 36-44

  Mori, Yoko ^a   Kondo, Chiaki ^a   Tonomura, Yutaka ^a   Torii, Mikinori ^a   Uehara, Takeki ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Biomarker; Cardiotoxicity; Rat; Toxicogenomics

Indexed keywords

BIOLOGICAL MARKER; CARBOFURAN; DOXORUBICIN; FHL1 PROTEIN; ISOPRENALINE; MONOCYTE CHEMOTACTIC PROTEIN 3; OSTEOPONTIN; REGENERATING ISLET DERIVED 3BETA PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL PROLIFERATION; CELL STRUCTURE; CHEMOTAXIS; CONTROLLED STUDY; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; INFLAMMATION; MALE; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DEGENERATION; TISSUE REGENERATION; TOXICOGENETICS; UPREGULATION;

ANIMALS; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CARBOFURAN; CARDIOMYOPATHIES; CARDIOTOXINS; CHEMOKINE CCL7; CLUSTER ANALYSIS; DOXORUBICIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; ISOPROTERENOL; LECTINS, C-TYPE; MALE; MUSCLE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

RATTUS;

EID: 77951298886     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.02.015     Document Type: Article

References (64)

1. Averill S., Davis D.R., Shortland P.J., Priestley J.V., Hunt S.P. Dynamic pattern of reg-2 expression in rat sensory neurons after peripheral nerve injury. J. Neurosci. 2002, 22:7493-7501.
2. Babuin L., Jaffe A.S. Troponin: the biomarker of choice for the detection of cardiac injury. Can. Med. Assoc. J. 2005, 173:1191-1202.
3. Barton P.J., Birks E.J., Felkin L.E., Cullen M.E., Koban M.U., Yacoub M.H. Increased expression of extracellular matrix regulators TIMP1 and MMP1 in deteriorating heart failure. J. Heart Lung Transplant. 2003, 22:738-744.
4. Battershill J.M. Toxicogenomics: regulatory perspective on current position. Hum. Exp. Toxicol. 2005, 24:35-40.
5. Berthiaume J.M., Wallace K.B. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 2007, 23:15-25.
6. Boyd J.W. Serum enzymes in the diagnosis of disease in man and animals. J. Comp. Pathol. 1988, 98:381-404.
7. Broder H., Gottlieb R.A., Lepor N.E. Chemotherapy and cardiotoxicity. Rev. Cardiovasc. Med. 2008, 9:75-83.
8. Chu P.H., Ruiz-Lozano P., Zhou Q., Cai C., Chen J. Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system. Mech. Dev. 2000, 95:259-265.
9. Decristofaro M.F., Daniels K.K. Toxicogenomics in biomarker discovery. Methods Mol. Biol. 2008, 460:185-194.
10. Doroshow J.H., Tallent C., Schechter J.E. Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity. Am. J. Pathol. 1985, 118:288-297.
11. Fabre N., Anglade I., Vericat J.A. Application of toxicogenomic tools in the drug research and development process. Toxicol. Lett. 2009, 186:13-17.
12. Ferreira A.L., Matsubara L.S., Matsubara B.B. Anthracycline-induced cardiotoxicity. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6:278-281.
13. Fung M., Thornton A., Mybeck K., Hsiao-Hui W., Hornbuckle K., Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Info. J. 2001, 35:293-317.
14. Gaussin V., Tomlinson J.E., Depre C., Engelhardt S., Antos C.L., Takagi G., Hein L., Topper J.N., Liggett S.B., Olson E.N., Lohse M.J., Vatner S.F., Vatner D.E. Common genomic response in different mouse models of beta-adrenergic-induced cardiomyopathy. Circulation 2003, 108:2926-2933.
15. Ge F., He Q.Y. Genomic and proteomic approaches for predicting toxicity and adverse drug reactions. Expert Opin. Drug Metab. Toxicol. 2009, 5:29-37.
16. Gupta R.C., Goad J.T., Kadel W.L. Carbofuran-induced alterations (in vivo) in high-energy phosphates, creatine kinase (CK) and CK isoenzymes. Arch. Toxicol. 1991, 65:304-310.
17. Gupta S., de Lemos J.A. Use and misuse of cardiac troponins in clinical practice. Prog. Cardiovasc. 2007, 50:151-165.
18. Halili-Rutman I., Hershko C., Link G., Rutman A.J., Shainberg A. Inhibition of calcium accumulation by the sarcoplasmic reticulum: a putative mechanism for the cardiotoxicity of adriamycin. Biochem. Pharmacol. 1997, 54:211-214.
19. Heinloth A.N., Irwin R.D., Boorman G.A., Nettesheim P., Fannin R.D., Sieber S.O., Snell M.L., Tucker C.J., Li L., Travlos G.S., Vansant G., Blackshear P.E., Tennant R.W., Cunningham M.L., Paules R.S. Gene expression profiling of rat livers reveals indicators of potential adverse effects. Toxicol. Sci. 2004, 80:193-202.
20. Iqbal M., Dubey K., Anwer T., Ashish A., Pillai K.K. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol. Rep. 2008, 60:382-390.
21. Irwin R.D., Boorman G.A., Cunningham M.L., Heinloth A.N., Malarkey D.E., Paules R.S. Application of toxicogenomics to toxicology: basic concepts in the analysis of microarray data. Toxicol. Pathol. 2004, 32:72-83.
22. Kondo C., Minowa Y., Uehara T., Okuno Y., Nakatsu N., Ono A., Maruyama T., Kato I., Yamate J., Yamada H., Ohno Y., Urushidani T. Identification of genomic biomarkers for concurrent diagnosis of drug-induced renal tubular injury using a large-scale toxicogenomics database. Toxicology 2009, 265:15-26.
23. Kaya Z., Göser S., Buss S.J., Leuschner F., Ottl R., Li J., Völkers M., Zittrich S., Pfitzer G., Rose N.R., Katus H.A. Identification of cardiac troponin I sequence motifs leading to heart failure by induction of myocardial inflammation and fibrosis. Circulation 2008, 118:2063-2072.
24. Kelishomi R.B., Ejtemaeemehr S., Tavangar S.M., Rahimian R., Mobarakeh J.I., Dehpour A.R. Morphine is protective against doxorubicin-induced cardiotoxicity in rat. Toxicology 2008, 243:96-104.
25. Kikkawa R., Fujikawa M., Yamamoto T., Hamada Y., Yamada H., Horii I. In vivo hepatotoxicity study of rats in comparison with in vitro hepatotoxicity screening system. J. Toxicol. Sci. 2006, 31:23-34.
26. Klein J., Gonzalez J., Duchene J., Esposito L., Pradère J.P., Neau E., Delage C., Calise D., Ahluwalia A., Carayon P., Pesquero J.B., Bader M., Schanstra J.P., Bascands J.L. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J. 2009, 23:134-142.
27. Komatsubara I., Murakami T., Kusachi S., Nakamura K., Hirohata S., Hayashi J., Takemoto S., Suezawa C., Ninomiya Y., Shiratori Y. Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats. Cardiovasc. Pathol. 2003, 12:186-194.
28. Korff S., Katus H.A., Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006, 92:987-993.
29. L'Ecuyer T., Sanjeev S., Thomas R., Novak R., Das L., Campbell W., Heide R.V. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:1273-1280.
30. Lee S.M., Tsui S.K., Chan K.K., Garcia-Barcelo M., Waye M.M., Fung K.P., Liew C.C., Lee C.Y. Chromosomal mapping, tissue distribution and cDNA sequence of four-and-a-half LIM domain protein 1 (FHL1). Gene 1998, 216:163-170.
31. Lenga Y., Koh A., Perera A.S., McCulloch C.A., Sodek J., Zohar R. Osteopontin expression is required for myofibroblast differentiation. Circ. Res. 2008, 102:319-327.
32. Li K., Sung R.Y., Huang W.Z., Yang M., Pong N.H., Lee S.M., Chan W.Y., Zhao H., To M.Y., Fok T.F., Li C.K., Wong Y.O., Ng P.C. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006, 113:2211-2220.
33. Liehn E.A., Merx M.W., Postea O., Becher S., Djalali-Talab Y., Shagdarsuren E., Kelm M., Zernecke A., Weber C. Ccr1 deficiency reduces inflammatory remodelling and preserves left ventricular function after myocardial infarction. J. Cell. Mol. Med. 2008, 12:496-506.
34. Lieu H.T., Batteux F., Simon M.T., Cortes A., Nicco C., Zavala F., Pauloin A., Tralhao J.G., Soubrane O., Weill B., Bréchot C., Christa L. HIP/PAP accelerates liver regeneration and protects against acetaminophen injury in mice. Hepatology 2005, 42:618-626.
35. Lim D.S., Roberts R., Marian A.J. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. J. Am. Coll. Cardiol. 2001, 38:1175-1180.
36. Loeb W.F. The rat. The Clinical Chemistry of Laboratory Animals 1999, 33-48. Taylor and Francis. W.F. Loeb, F.W. Quimby (Eds.).
37. Mikaelian I., Coluccio D., Morgan K.T., Johnson T., Ryan A.L., Rasmussen E., Nicklaus R., Kanwal C., Hilton H., Frank K., Fritzky L., Wheeldon E.B. Temporal gene expression profiling indicates early up-regulation of interleukin-6 in isoproterenol-induced myocardial necrosis in rat. Toxicol. Pathol. 2008, 36:256-264.
38. Milting H., Ellinghaus P., Seewald M., Cakar H., Bohms B., Kassner A., Körfer R., Klein M., Krahn T., Kruska L., El Banayosy A., Kramer F. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J. Heart Lung Transplant. 2008, 27:589-596.
39. O'Brien P.J. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 2008, 245:206-218.
40. Ong V.H., Carulli M.T., Xu S., Khan K., Lindahl G., Abraham D.J., Denton C.P. Cross-talk between MCP-3 and TGFbeta promotes fibroblast collagen biosynthesis. Exp. Cell Res. 2009, 315:151-161.
41. Ong V.H., Evans L.A., Shiwen X., Fisher I.B., Rajkumar V., Abraham D.J., Black C.M., Denton C.P. Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum. 2003, 48:1979-1991.
42. Osman A.M., Nemnem M.M., Abou-Bakr A.A., Nassier O.A., Khayyal M.T. Effect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice. Food Chem. Toxicol. 2009, 47:2425-2430.
43. Remondino A., Kwon S.H., Communal C., Pimentel D.R., Sawyer D.B., Singh K., Colucci W.S. Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ. Res. 2003, 92:136-138.
44. Saha J.K., Xia J., Sandusky G.E., Chen Y.F., Gerlitz B., Grinnell B., Jakubowski J.A. Study of plasma protein C and inflammatory pathways: biomarkers for dimethylnitrosamine-induced liver fibrosis in rats. Eur. J. Pharmacol. 2007, 575:158-167.
45. Satoh M., Nakamura M., Akatsu T., Shimoda Y., Segawa I., Hiramori K. Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. Eur. J. Heart Fail. 2005, 7:755-762.
46. Searfoss G.H., Ryan T.P., Jolly R.A. The role of transcriptome analysis in pre-clinical toxicology. Curr. Mol. Med. 2005, 5:53-64.
47. Sheikh F., Raskin A., Chu P.H., Lange S., Domenighetti A.A., Zheng M., Liang X., Zhang T., Yajima T., Gu Y., Dalton N.D., Mahata S.K., Dorn G.W., Heller-Brown J., Peterson K.L., Omens J.H., McCulloch A.D., Chen J. An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice. J. Clin. Invest. 2008, 118:3870-3880.
48. Singer A.W., Jaax N.K., Graham J.S., McLeod C.G. Cardiomyopathy in soman and sarin intoxicated rats. Toxicol. Lett. 1987, 36:243-249.
49. Stawowy P., Blaschke F., Pfautsch P., Goetze S., Lippek F., Wollert-Wulf B., Fleck E., Graf K. Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur. J. Heart Fail. 2002, 4:139-146.
50. Szalay G., Sauter M., Haberland M., Zuegel U., Steinmeyer A., Kandolf R., Klingel K. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ. Res. 2009, 104:851-859.
51. Tebar L.A., Géranton S.M., Parsons-Perez C., Fisher A.S., Bayne R., Smith A.J., Turmaine M., Perez-Luz S., Sheasby A., De Felipe C., Ruff C., Raivich G., Hunt S.P. Deletion of the mouse RegIIIbeta (Reg2) gene disrupts ciliary neurotrophic factor signaling and delays myelination of mouse cranial motor neurons. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11400-11405.
52. Thukral S.K., Nordone P.J., Hu R., Sullivan L., Galambos E., Fitzpatrick V.D., Healy L., Bass M.B., Cosenza M.E., Afshari C.A. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol. Pathol. 2005, 33:343-355.
53. Toeda K., Nakamura K., Hirohata S., Hatipoglu O.F., Demircan K., Yamawaki H., Ogawa H., Kusachi S., Shiratori Y., Ninomiya Y. Versican is induced in infiltrating monocytes in myocardial infarction. Mol. Cell Biochem. 2005, 280:47-56.
54. Tonomura Y., Mori Y., Torii M., Uehara T. Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats. Toxicology 2009, 266:48-54.
55. Trueblood N.A., Xie Z., Communal C., Sam F., Ngoy S., Liaw L., Jenkins A.W., Wang J., Sawyer D.B., Bing O.H., Apstein C.S., Colucci W.S., Singh K. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ. Res. 2001, 88:1080-1087.
56. Tryphanas L., Veinot J.P., Clement J.G. Early histopathological and ultrastructural changes in the heart of Sprague-Dawley rats following administration of soman. Toxicol. Pathol. 1996, 24:190-198.
57. Wang E.J., Snyder R.D., Fielden M.R., Smith R.J., Gu Y.Z. Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology 2008, 246:91-100.
58. Watanabe R., Hanawa H., Yoshida T., Ito M., Isoda M., Chang H., Toba K., Yoshida K., Kojima M., Otaki K., Ding L., Hao K., Kato K., Kodama M., Aizawa Y. Gene expression profiles of cardiomyocytes in rat autoimmune myocarditis by DNA microarray and increase of regenerating gene family. Transl. Res. 2008, 152:119-127.
59. Wolf M.B., Baynes J.W. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim. Biophys. Acta 2006, 1760:267-271.
60. Yang A., Trajkovic D., Illanes O., Ramiro-Ibáñez F. Clinicopathological and tissue indicators of para-aminophenol nephrotoxicity in Sprague-Dawley rats. Toxicol. Pathol. 2007, 35:521-532.
61. Yi X., Bekeredjian R., DeFilippis N.J., Siddiquee Z., Fernandez E., Shohet R.V. Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:1098-1102.
62. Zahradka P. Novel role for osteopontin in cardiac fibrosis. Circ. Res. 2008, 102:319-327.
63. Zhang G.X., Ohmori K., Nagai Y., Fujisawa Y., Nishiyama A., Abe Y., Kimura S. Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. J. Mol. Cell Cardiol. 2007, 42:804-811.
64. Zhang J., Knapton A., Lipshultz S.E., Weaver J.L., Herman E.H. Isoproterenol-induced cardiotoxicity in Sprague-Dawley rats: correlation of reversible and irreversible myocardial injury with release of cardiac troponin T and roles of iNOS in myocardial injury. Toxicol. Pathol. 2008, 36:277-278.